» Articles » PMID: 35477657

Boosting the Peripheral Immune Response in the Skeletal Muscles Improved Motor Function in ALS Transgenic Mice

Overview
Journal Mol Ther
Publisher Cell Press
Date 2022 Apr 28
PMID 35477657
Authors
Affiliations
Soon will be listed here.
Abstract

Monocyte chemoattractant protein-1 (MCP1) is one of the most powerful pro-inflammatory chemokines. However, its signaling is pivotal in driving injured axon and muscle regeneration. We previously reported that MCP1 is more strongly upregulated in the nervous system of slow-progressing than fast-progressing SOD1 mice, the latter showing a poor immune response and eventual massive nerve and muscle degeneration. To assess the MCP1-mediated therapeutic role, we boosted the chemokine along the motor unit of the two SOD1 models through a single intramuscular injection of a scAAV9 vector engineered with the Mcp1 gene. We provided direct evidence underlying the pivotal role of the immune response in driving skeletal muscle regeneration and thus the speed of ALS progression. The comparative study performed in fast- and slow-progressing SOD1 mice spotlights the nature and temporal activation of the inflammatory response as limiting factors to preserve the periphery and interfere with the disease course. In addition, we recorded a novel pleiotropic role of MCP1 in promoting peripheral axon regeneration and modulating neuroinflammation, ultimately preventing neurodegeneration. Altogether, these observations highlight the immune response as a key determinant for disease variability and proffer a reasonable explanation for the failure of systemic immunomodulatory treatments, suggesting new potential strategies to hamper ALS progression.

Citing Articles

The myokine FGF21 associates with enhanced survival in ALS and mitigates stress-induced cytotoxicity.

Guha A, Si Y, Smith R, Kazamel M, Jiang N, Smith K bioRxiv. 2024; .

PMID: 39314333 PMC: 11419072. DOI: 10.1101/2024.09.11.611693.


Therapeutics Targeting Skeletal Muscle in Amyotrophic Lateral Sclerosis.

Gao J, Sterling E, Hankin R, Sikal A, Yao Y Biomolecules. 2024; 14(7).

PMID: 39062592 PMC: 11275039. DOI: 10.3390/biom14070878.


Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies.

Dashtmian A, Darvishi F, Arnold W Cells. 2024; 13(11.

PMID: 38891059 PMC: 11171952. DOI: 10.3390/cells13110928.


Multiomic ALS signatures highlight subclusters and sex differences suggesting the MAPK pathway as therapeutic target.

Caldi Gomes L, Hanzelmann S, Hausmann F, Khatri R, Oller S, Parvaz M Nat Commun. 2024; 15(1):4893.

PMID: 38849340 PMC: 11161513. DOI: 10.1038/s41467-024-49196-y.


Neutrophils: a subgroup of neglected immune cells in ALS.

Cao W, Fan D Front Immunol. 2023; 14:1246768.

PMID: 37662922 PMC: 10468589. DOI: 10.3389/fimmu.2023.1246768.


References
1.
Chen P, Piao X, Bonaldo P . Role of macrophages in Wallerian degeneration and axonal regeneration after peripheral nerve injury. Acta Neuropathol. 2015; 130(5):605-18. DOI: 10.1007/s00401-015-1482-4. View

2.
Lauranzano E, Pozzi S, Pasetto L, Stucchi R, Massignan T, Paolella K . Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes. Brain. 2015; 138(Pt 4):974-91. DOI: 10.1093/brain/awv005. View

3.
Tofaris G, Patterson P, Jessen K, Mirsky R . Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J Neurosci. 2002; 22(15):6696-703. PMC: 6758146. DOI: 20026699. View

4.
Schafer S, Hermans E . Reassessment of motor-behavioural test analyses enables the detection of early disease-onset in a transgenic mouse model of amyotrophic lateral sclerosis. Behav Brain Res. 2011; 225(1):7-14. DOI: 10.1016/j.bbr.2011.06.019. View

5.
Kano O, Beers D, Henkel J, Appel S . Peripheral nerve inflammation in ALS mice: cause or consequence. Neurology. 2012; 78(11):833-5. PMC: 3304948. DOI: 10.1212/WNL.0b013e318249f776. View